Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 17/20 | 0.43 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.40 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2291309 | 0.93 | GCK (0.46) | GCKCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2292896 | 0.92 | GCK (0.46) | GCKCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1659721 | 0.90 | GCK (0.54) | GCKCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2295322 | 0.85 | GCK (0.47) | GCKCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2645659 | 0.85 | GCK (0.51) | GCKCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2293097 | 0.83 | GCK (0.42) | GCKCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1657079 | 0.83 | GCK (0.57) | GCK | |
| SCHEMBL1657389 | 0.82 | GCK (0.57) | GCK | |
| SCHEMBL2644571 | 0.82 | GCK (0.47) | GCKCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2294094 | 0.82 | GCK (0.57) | GCKCYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932394-B2 | 1-{[5-[4-(Methylsulfonyl)phenoxy]-2-(2-pyridinyl)-1H-benzimidazol-6-yl]methyl}-5-thioxo-2-pyrrolidinone;glucokinase activator; antidiabetic agents; obesity; prevention of retinopathy, nephropathy, neurosis, ischemic cardiopathy, arteriosclerosis; antiischemic agents; cardiotonic agents | MSD K.K. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20080125429-A1 | Aryloxy-Substituted Benzimidazole Derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-05-29 | — | — | US | disclosed |
| EP-1810969-A1 | ARYLOXY-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125429-A1 | Aryloxy-Substituted Benzimidazole Derivatives | GCK, GCKR, SLC5A1 | GCK 1/4885PKN1 721/4885PKN2 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.